|1.||Elhilali, Mostafa: 7 articles (04/2008 - 03/2005)|
|2.||Matzkin, Haim: 6 articles (06/2008 - 03/2005)|
|3.||Emberton, Mark: 6 articles (04/2008 - 03/2005)|
|4.||Vallancien, Guy: 6 articles (04/2008 - 03/2005)|
|5.||Roehrborn, C G: 6 articles (09/2007 - 03/2001)|
|6.||Alcaraz, Antonio: 5 articles (04/2008 - 03/2005)|
|7.||Roehrborn, Claus G: 5 articles (01/2008 - 11/2003)|
|8.||Nickel, J Curtis: 4 articles (12/2008 - 09/2003)|
|9.||ALF-ONE Study Group: 4 articles (04/2008 - 03/2005)|
|10.||Hartung, Rudolf: 4 articles (04/2008 - 03/2005)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
12/01/2001 - "The results of 2 double-blind, placebo-controlled phase 3 studies in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia suggests that 10 mg of alfuzosin administered once daily without dose titration is superior to placebo in terms of symptom and urinary flow rate improvement. "
02/01/2013 - "The purpose of present research was to develop and optimize sustained release floating pellets of alfuzosin hydrochloride which has narrow absorption window in proximal intestine to improve patient compliance and therapeutic efficacy in the treatment of benign prostatic hyperplasia. "
04/01/2000 - "Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice."
01/01/2002 - "To evaluate the long-term safety and efficacy of a new, once-daily (o.d.) prolonged-release formulation of the clinically uroselective alpha1-blocker, alfuzosin, in patients with symptomatic benign prostatic hyperplasia (BPH). "
12/01/2001 - "Alfuzosin 10 mg OD, administered without dose titration, provides effective relief from the symptoms of benign prostatic hyperplasia with no additional benefit from a 15-mg dose. "
09/01/2003 - "Six months of alfuzosin therapy for CP/CPPS is safe and well tolerated and results in a modest, but statistically significant, improvement in the NIH-CPSI, particularly in the pain domain, compared with placebo and standard/traditional treatment. "
09/01/2003 - "A statistically significant improvement occurred in the pain score in the alfuzosin group at 6 months compared with the placebo and control/standard groups (P = 0.01), but not in the voiding or quality-of-life score among the three groups. "
01/01/2004 - "The results were encouraging: almost all the patients eliminated the stones without any pain in the first 5-10 days of treatment (only two patients from alfuzosin group did not tolerate this drug). "
06/01/2006 - "In all, 4857 sexually active men with LUTS had an evaluable answer to the Danish Prostate Symptom Score for Sexual Symptoms question related to pain/discomfort on ejaculation at enrolment in a 6-month open-label study with alfuzosin 10 mg once daily. "
07/01/2011 - "To assess the spontaneous passage rate for patients being treated with alfuzosin 10mg daily after presenting with an acute ureteral stone compared with a control group, and to assess the respective pain control status. "
09/01/2002 - "A significant reduction of residual urine was observed only occasionally, but at least alfuzosin is able to reduce the incidence of acute urinary retention. "
10/01/1999 - "Treatment with SR alfuzosin is effective in improving the success rate of a TWOC after an episode of acute urinary retention, although older patients are less likely to void successfully. "
10/01/2002 - "We conducted a study to evaluate the efficacy of using the alpha-blocker alfuzosin SR in patients with acute urinary retention. "
01/01/2005 - "Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study."
10/01/1999 - "In a prospective, randomized, placebo-controlled trial, 81 patients with acute urinary retention related to benign prostatic obstruction received either SR alfuzosin (n=40), an alpha1-selective blocker, given at a dose of 5 mg twice daily, or placebo (n=41) for 48 h. "
08/01/2012 - "Prolonged-release alfuzosin effectively improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH and mild to severe erectile dysfunction. "
09/01/2010 - "Secondary objectives were to evaluate the efficacy of alfuzosin on LUTS, bother score (International Prostate Symptom Score [IPSS] 8th question), erectile dysfunction (ED), onset of action, and tolerability. "
03/01/2015 - "With prolonged-release alfuzosin, they were 2.8% vs. 1.3% for erectile dysfunction, compared to placebo and 1% vs. 0% for ejaculatory dysfunction. "
12/01/2008 - "To determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective alpha1-adrenoceptor antagonist, alfuzosin (Sanofi-Aventis, Paris, France) attenuates any erectile dysfunction (ED). "
12/01/2008 - "Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction."
12/01/2006 - "Recent studies have suggested the potential efficacy of alfuzosin in the treatment of distal ureteral stones and prostatitis syndrome, two conditions frequently encountered in young patients. "
12/01/2006 - "This study shows that alfuzosin 10mg is well tolerated by young healthy subjects and may therefore be safely administered to young normotensive patients affected by distal ureteral stones and prostatitis."
06/01/2006 - "This 6-month open-label study suggests that alfuzosin 10 mg once daily significantly improves LUTS, quality of life and sexual function in men with prostatitis-like symptoms, and is well tolerated."
01/01/1992 - "A double-blind, placebo-controlled study in 20 patients with 'prostatitis syndromes' and confirmed urodynamic abnormalities using the alpha 1-receptor-blocking compound alfuzosin is reported. "
01/01/1992 - "Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities."
|10.||Adrenergic Receptors (Adrenergic Receptor)
|1.||Transurethral Resection of Prostate (TURP)
|3.||Lithotripsy (Extracorporeal Shockwave Lithotripsy)